Researchers at St. Jude have created methods for the identification of cancers that are resistant to or are genetically predisposed to be resistant to Anaplastic Lymphoma Kinase (ALK) inhibitors based on the discovery of 15 novel mutations in ALK that confer resistance to ALK kinase inhibitors. ALK inhibitor-resistance mutant polypeptides and polynucleotides encoding the same are biomarkers for detecting mutations and in diagnosing those cancers that are resistant or likely to develop resistance to ALK kinase inhibitors.
This technology specifically deals with the diagnostic tests that are useful for patients who could be prescribed ALK class cancer drugs.
Anaplastic Lymphoma Kinase, ALK inhibitors, detect, diagnose
Granted Patents or Published Applications
Issued patents in the US (8,383,793 and 9,458,508), Europe (2558490) and China (ZL201180023776) and pending applications in Canada, Australia and Japan
Related Scientific References
Rights are become available in January, 2018 for exclusive or nonexclusive licensing. Contact: firstname.lastname@example.org
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.